BACKGROUND: Small cell undifferentiated (SCU) histology in patients with stage I hepatoblastoma (HB) predicts an increased risk of relapse. We sought to determine the significance of SCU histology in patients with unresectable HB. PROCEDURE: Patients enrolled on the pediatric Intergroup (INT0098) trial for HB and patients from the personal consultation files of two of the authors (MF, LG) were reviewed for cases with SCU histology. These patients were compared with SCU HB patients identified by literature review. RESULTS: Eleven patients were studied. All patients with reported AFP results exhibited normal or minimally increased serum AFP levels. None of the patients survived: 10 died of disease progression, and 1 died from treatment complications. Immunostaining revealed that tumors from six of six patients tested were INI1 negative. Cytogenetic and molecular abnormalities in one patient (and two patients from the literature review) were similar to those described in rhabdoid tumors. Comparison with patients from the literature review revealed similar results except that 4 of 29 patients survived without evidence of disease. CONCLUSIONS: SCU histology in HB patients is associated with an adverse outcome. These tumors appear to be biologically different from non-SCU HB. Evaluation of patient characteristics and outcomes for children with SCU HB and/or those with low AFP levels should be determined from large cooperative group studies. In the meantime, we suggest patients with unresectable HB containing SCU elements have careful cytogenetic, molecular, and immunohistochemical evaluation to ascertain rhabdoid features and receive treatment that differs from that provided for other HB patients.
BACKGROUND: Small cell undifferentiated (SCU) histology in patients with stage I hepatoblastoma (HB) predicts an increased risk of relapse. We sought to determine the significance of SCU histology in patients with unresectable HB. PROCEDURE: Patients enrolled on the pediatric Intergroup (INT0098) trial for HB and patients from the personal consultation files of two of the authors (MF, LG) were reviewed for cases with SCU histology. These patients were compared with SCU HB patients identified by literature review. RESULTS: Eleven patients were studied. All patients with reported AFP results exhibited normal or minimally increased serum AFP levels. None of the patients survived: 10 died of disease progression, and 1 died from treatment complications. Immunostaining revealed that tumors from six of six patients tested were INI1 negative. Cytogenetic and molecular abnormalities in one patient (and two patients from the literature review) were similar to those described in rhabdoid tumors. Comparison with patients from the literature review revealed similar results except that 4 of 29 patients survived without evidence of disease. CONCLUSIONS: SCU histology in HB patients is associated with an adverse outcome. These tumors appear to be biologically different from non-SCU HB. Evaluation of patient characteristics and outcomes for children with SCU HB and/or those with low AFP levels should be determined from large cooperative group studies. In the meantime, we suggest patients with unresectable HB containing SCU elements have careful cytogenetic, molecular, and immunohistochemical evaluation to ascertain rhabdoid features and receive treatment that differs from that provided for other HB patients.
Authors: B Gunawan; K-L Schäfer; B Sattler; T Lorf; B Dockhorn-Dworniczak; B Ringe; L Füzesi Journal: Histopathology Date: 2002-05 Impact factor: 5.087
Authors: Marcio H Malogolowkin; Howard M Katzenstein; Rebecka L Meyers; Mark D Krailo; Jon M Rowland; Joel Haas; Milton J Finegold Journal: J Clin Oncol Date: 2011-07-18 Impact factor: 44.544
Authors: J A Ortega; E C Douglass; J H Feusner; M Reynolds; J J Quinn; M J Finegold; J E Haas; D R King; W Liu-Mares; M G Sensel; M D Krailo Journal: J Clin Oncol Date: 2000-07 Impact factor: 44.544
Authors: Lisa M Sullivan; Theresa Yankovich; Paul Le; Daniel Martinez; Mariarita Santi; Jaclyn A Biegel; Bruce R Pawel; Alexander R Judkins Journal: Am J Surg Pathol Date: 2012-01 Impact factor: 6.394
Authors: Howard M Katzenstein; Wayne L Furman; Marcio H Malogolowkin; Mark D Krailo; M Beth McCarville; Alexander J Towbin; Greg M Tiao; Milton J Finegold; Sarangarajan Ranganathan; Stephen P Dunn; Max R Langham; Eugene D McGahren; Carlos Rodriguez-Galindo; Rebecka L Meyers Journal: Cancer Date: 2017-02-17 Impact factor: 6.860
Authors: Marcio H Malogolowkin; Howard M Katzenstein; Rebecka L Meyers; Mark D Krailo; Jon M Rowland; Joel Haas; Milton J Finegold Journal: J Clin Oncol Date: 2011-07-18 Impact factor: 44.544
Authors: Min Yang; Xi Chen; Ning Wang; Kun Zhu; Ying-Zi Hu; Yun Zhao; Yan Shu; Man-Li Zhao; Wei-Zhong Gu; Hong-Feng Tang Journal: Int J Clin Exp Pathol Date: 2014-04-15
Authors: Xi Wang; Courtney G Sansam; Christopher S Thom; Daniel Metzger; Julia A Evans; Phuong T L Nguyen; Charles W M Roberts Journal: Cancer Res Date: 2009-09-29 Impact factor: 12.701